Trial · NCT07881705
A Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer
NCT07881705, Phase 3, Active not recruiting, Jiangsu Simcere Pharmaceutical Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer. Trials, record NCT07881705. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07881705
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer
- NCT number
- NCT07881705
- Status
- Active not recruiting
- Phases
- Phase 3
- Enrollment
- 106 participants, actual
- Lead sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Conditions
- Myelosuppression
- Interventions
- Trilaciclib, Trilaciclib Placebo, Etoposide Injection, Carboplatin or Cisplatin Injection, Radiotherapy
- First posted
- 2026-10-19
- Last updated
- 2026-10-19
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The duration of severe neutropenia (DSN) in cycle 1 | During the first cycle (each cycle is 21 days) | The time duration of absolute neutrophil count (ANC) decrease meeting Grade 4 per NCI CTCAE 5.0 (i.e., ANC \< 0.5 × 10⁹/L). |
| Primary | The incidence of severe neutropenia (SN) | From the time of first dosing until 30 days after the end of study treatment, up to about 3.5 months | The incidence of absolute neutrophil count (ANC) decrease meeting Grade 4 per NCI CTCAE 5.0 (i.e., ANC \< 0.5 × 10⁹/L). |
| Secondary | Granulocyte colony-stimulating factor (G-CSF) utilization rate | From the time of first dosing until 30 days after the end of study treatment, up to about 3.5 months | |
| Secondary | Incidence of febrile neutropenia | From the time of first dosing until 30 days after the end of study treatment, up to about 3.5 months | |
| Secondary | The lowest absolute neutrophil count in each cycle | From the time of first dosing until 30 days after the end of study treatment, up to about 3.5 months] | |
| Secondary | Incidence of grade ≥3 hemoglobin decrease | From the time of first dosing until 30 days after the end of study treatment, up to about 3.5 month | |
| Secondary | Incidence of red blood cell transfusions (from Week 5 onward) | From Week 5 until 30 days after the end of study treatment, up to about 3 months | |
| Secondary | Erythropoiesis-stimulating agent (ESA) utilization rate | From the time of first dosing until 30 days after the end of study treatment, up to about 3.5 months | |
| Secondary | Incidence of grade ≥3 platelet count decrease | From the time of first dosing until 30 days after the end of study treatment, up to about 3.5 months | |
| Secondary | Incidence of platelet transfusions | From the time of first dosing until 30 days after the end of study treatment, up to about 3.5 months. |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07881705
GET https://conductscience.org/api/trials/v1/NCT07881705/registered